Table 2.
Cytotoxicity of Capuramycin, Capuramycin Analogues, and Tunicamycin.
| Entry | Compound | IC50 (μM)a | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L1210 | KB | SiHa | HCT-116 | DLD-1 | Capan-1 | PANC-1 | AsPC-1 | PD002 | HPNE | Vero | ||
| 1 | CAP (1) | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
| 2 | OM-CAP (2) | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
| 3 | CPPB (5) | >50 | 35.0 | 15.0 | 15.0 | 25.0 | 30.0 | 35.0 | 25.0 | 35.0 | >50 | >50 |
| 4 | I-CPPB (6) | >50 | 35.0 | 25.0 | 25.0 | 35.0 | 40.0 | 45.0 | 30.0 | 50.0 | >50 | >50 |
| 5 | Tunicamycin (11) | 1.70 | 2.50 | 0.92 | 0.92 | 1.25 | 1.50 | 1.50 | 0.45 | 1.50 | 7.5 | 0.78 |
CAP: Capuramycin.; OM-CAP: O-Methyl capuramycin.; CPPB: Capuramycin phenoxypiperidinylbenzylamide.; I-CCB: iso-Capuramycin phenoxypiperidinylbenzylamide.; L1210 (ATCC® CCL-219™): mouse lymphocytic leukemia.; KB (ATCC® CCL-17™): HeLa, human cervical carcinoma.; SiHa (ATCC® HTB-35™): human cervical squamous cell carcinoma.; HCT-116 (ATCC® CCL-247™): colorectal adenocarcinoma.; DLD-1 (ATCC® CCL221™): colorectal adenocarcinoma.; Capan-1 (ATCC® HTB-79™): pancreatic ductal adenocarcinoma.; PANC-1 (ATCC® CRL-1469™): pancreatic ductal carcinoma.; AsPC-1 (ATCC® CRL-1682™): pancreatic adenocarcinoma.; PD002: a pancreatic adenocarcinoma staged at T3N1M0 from a 55 years old Caucasian male in 2011 (provided by Dr. Glazer (University of Tennessee Health Science Center).; hTERT-HPNE (ATCC® CRL-4023™): normal pancreatic ductal cell.; Vero (ATCC® CCL-81™): normal Cercopithecus aethiops kidney cell.
IC50 values were determined via MTT assay.